The endTB-Q clinical trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of a new, all-oral, shortened regimen for fluoroquinolone-resistant multidrug-resistant tuberculosis (MDR-TB). Experimental treatment duration is 6 to 9 months, defined for each participant according to disease extension at baseline and on-treatment response. endTB-Q is currently enrolling participants across six sites in four countries (India, Pakistan, Peru, Vietnam). Primary outcome results are expected for late 2024.
endTB-Q experimental regimen: Bdq-Cfz-Dlm-Lzd
For more information on this trial, visit the project website at http://www.endtb.org/clinical-trial
Registry Link